The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
Open accessPublished version of a preprint
Abstract
Over the past 20 years, several coronaviruses have crossed the species barrier into humans, causing outbreaks of severe, and often fatal, respiratory illness. Since SARS-CoV was first identified in animal markets, global viromics projects have discovered thousands of coronavirus sequences in diverse animals and geographic regions. Unfortunately, there are few tools available to functionally test these viruses for their ability to infect humans, which has severely hampered efforts to predict the next zoonotic viral outbreak. Here, we developed an approach to rapidly screen lineage B betacoronaviruses, such as SARS-CoV and the recent SARS-CoV-2, for receptor usage and their ability to infect cell types from different species. We show that host protease processing during viral entry is a significant barrier for several lineage B viruses and that bypassing this barrier allows several lineage B viruses to enter human cells through an unknown receptor. We also demonstrate how different lineage B viruses can recombine to gain entry into human cells, and confirm that human ACE2 is the receptor for the recently emerging SARS-CoV-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The S protein mediates binding of coronaviruses to angiotensin converting enzyme 2 (ACE2) on the surface of various cell types including epithelial cells of the pulmonary alveolus (4–6).”
From An Alphavirus -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“it directly interacts with the cellular receptor angiotensin converting enzyme 2 (ACE2) which mediates host cell entry”
From SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 (2021) · cites this paper as Letko et al., 2020
In the citing paper
“SARS-CoV-2 is a single-stranded RNA β-coronavirus and a member of the subgenus Sarbecovirus (beta-CoV lineage B).”
From Oral Microbiome and SARS-CoV-2: Beware of Lung Co-infection (2020) · cites this paper as Letko et al., 2020
In the citing paper
“It is the seventh member of the Coronaviridae known to infect humans so far, two of which, SARS-CoV and MERS-CoV, caused global health threats previously (Guarner, 2020; Letko et al., 2020).”
From Oral Microbiome and SARS-CoV-2: Beware of Lung Co-infection (2020) · cites this paper as Letko et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341
Structure, Function, and Evolution of Coronavirus Spike Proteins
Li, F. (2016) · Annual Review of Virology · doi:10.1146/annurev-virology-110615-042301 · Cited by 2,740
Bats Are Natural Reservoirs of SARS-Like Coronaviruses
Li, W., Shi, Z., Yu, M., Ren, W., Smith, C. S., Epstein, J. H., Wang, H., Crameri, G. S., Hú, Z., Zhang, H., et al. (2005) · Science · doi:10.1126/science.1118391 · Cited by 2,571
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H. W., Müller, M. A., Dijkman, R., Muth, D., Demmers, J. A. A., Zaki, A., Fouchier, R. A. M., et al. (2013) · Nature · doi:10.1038/nature12005 · Cited by 2,061
Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor
Li, F., Li, W., Farzan, M., & Harrison, S. C. (2005) · Science · doi:10.1126/science.1116480 · Cited by 2,035
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
Ge, X.-Y., Li, J.-L., Yang, X.-L., Chmura, A. A., Zhu, G., Epstein, J. H., Mazet, J. K., Hu, B., Zhang, W., Peng, C., et al. (2013) · Nature · doi:10.1038/nature12711 · Cited by 1,778
Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats
Lau, S. K. P., Woo, P. C. Y., Li, K. S. M., Huang, Y. P., Tsoi, H., Wong, B. H. L., Wong, S. S. Y., Leung, S.-Y., Chan, K., & Yuen, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506735102 · Cited by 1,561
Belouzard, S., Chu, V. C., & Whittaker, G. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809524106 · Cited by 1,076
Cited by
Sorted by citations
Items 801–900 of 1,005
Understanding the Molecular Biology of SARS-CoV-2 and the COVID-19 Pandemic: A Review
Alsobaie, S. F. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s306441 · Cited by 42
Jomhori, M., Mosaddeghi, H., & Farzin, H. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104692 · Cited by 42
Chitinase 3-like-1 is a therapeutic target that mediates the effects of aging in COVID-19
Kamle, S., Ma, B., He, C. H., Akosman, B., Zhou, Y., Lee, C.-M., El‐Deiry, W. S., Huntington, K. E., Liang, O. D., Machan, J. T., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.148749 · Cited by 44
SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity
Zhang, F., Schmidt, F., Muecksch, F., Wang, Z., Gazumyan, A., Nussenzweig, M. C., Gaebler, C., Caskey, M. F., Hatziioannou, T., & Bieniasz, P. D. (2024) · mBio · doi:10.1128/mbio.01672-23 · Cited by 46
SARS-CoV-2 (COVID-19): New Discoveries and Current Challenges
Soufi, G. J., Hekmatnia, A., Nasrollahzadeh, M., Shafiei, N., Sajjadi, M., Iravani, P., Fallah, S., Iravani, S., & Varma, R. S. (2020) · Applied Sciences · doi:10.3390/app10103641 · Cited by 41
Ejuh, G. W., Fonkem, C. C., Assatse, Y. T., Kamsi, R. A. Y., Nya, F. T., Ndukum, L. P., & Ndjaka, J. M. B. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e04647 · Cited by 42
Deciphering SARS-CoV-2 Virologic and Immunologic Features
Lebeau, G., Vagner, D., Frumence, É., Ah-Pine, F., Guillot, X., Nobécourt, E., Raffray, L., & Gasque, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165932 · Cited by 54
Mukherjee, S., Mazumder, P., Joshi, M. N., Joshi, C. G., Dalvi, S. V., & Kumar, M. (2020) · Environmental Research · doi:10.1016/j.envres.2020.110119 · Cited by 42
Yang, L., Lu, H., Wang, W., Liu, Q., & Zhu, C. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1837628 · Cited by 42
Haidar, M. A., Jourdi, H., Hassan, Z. H., Ashekyan, O., Fardoun, M., Wehbe, Z., Maaliki, D. S., Wehbe, M., Mondello, S., Abdelhady, S., et al. (2021) · The Neuroscientist · doi:10.1177/1073858420984106 · Cited by 44
Vivar-Sierra, A., Araiza-Macías, M. J., Contreras, J. P. H., Vergara‐Castañeda, A., Ramírez-Vélez, G., Pinto‐Almazán, R., Salazar, J. R., & Loza-Mejía, M. A. (2021) · Molecules · doi:10.3390/molecules26030711 · Cited by 44
Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins
Bouwman, K. M., Tomris, I., Turner, H. L., van der Woude, R., Shamorkina, T. M., Bosman, G. P., Rockx, B., Herfst, S., Snijder, J., Haagmans, B. L., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009282 · Cited by 39
Overview of COVID-19 Disease: Virology, Epidemiology, Prevention Diagnosis, Treatment, and Vaccines
Salahshoori, I., Mobaraki-Asl, N., Seyfaee, A., Nasirabad, N. M., Dehghan, Z., Faraji, M., Ganjkhani, M., Babapoor, A., Shadmehr, S., & Hamrang, A. (2021) · Biologics · doi:10.3390/biologics1010002 · Cited by 46
Vagapova, E. R., Lebedev, T. D., & Prassolov, V. (2021) · Scientific Reports · doi:10.1038/s41598-021-90701-w · Cited by 43
Machado, R. R. G., Glaser, T., Araújo, D. B., Petiz, L. L., Oliveira, D. B. L., Durigon, G. S., Leal, A. L., Pinho, J. R. R., Ferreira, L. C. S., Ulrich, H., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00080 · Cited by 44
Shoshan‐Barmatz, V., Anand, U., Crystal, E. N., Carlo, M. D., & Shteinfer‐Kuzmine, A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.730048 · Cited by 42
Ma, L.-L., Liu, H.-M., Liu, X., Yuan, X., Xu, C., Wang, F., Lin, J., Xu, R., & Zhang, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113857 · Cited by 42
Longitudinal Plasma Proteomics Analysis Reveals Novel Candidate Biomarkers in Acute COVID-19
Mohammed, Y., Goodlett, D. R., Cheng, M. P., Vinh, D. C., Lee, T. C., McGeer, A., Sweet, D. D., Tran, K. C., Lee, T., Murthy, S., et al. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00863 · Cited by 41
Pollet, J. B. K., Strych, U., Chen, W., Versteeg, L., Keegan, B. P., Zhan, B., Wei, J., Liu, Z., Lee, J., Kundu, R., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.007 · Cited by 42
Roy, C., Mandal, S. M., Mondal, S. K., Mukherjee, S., Mapder, T., Ghosh, W., & Chakraborty, R. (2020) · Genomics · doi:10.1016/j.ygeno.2020.11.003 · Cited by 37
Long-term infection of SARS-CoV-2 changed the body's immune status
Lin, L., Luo, S., Qin, R., Yang, M., Wang, X., Yang, Q., Zhang, Y., Wang, Q., Zhu, R., Fan, H., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108524 · Cited by 42
Kumar, V. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106980 · Cited by 42
Targeting the viral‐entry facilitators of SARS‐CoV‐2 as a therapeutic strategy in COVID‐19
Muralidar, S., Gopal, G., & Ambi, S. V. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27019 · Cited by 42
Gao, T., Ren, Y., Li, S., Lü, X., & Han, L. (2021) · Microbial Cell Factories · doi:10.1186/s12934-021-01584-5 · Cited by 42
Zhao, Z., Feng, M., Wan, J., Zheng, X., Teng, C., Xie, X., Pan, W., Hu, B., Huang, J., Liu, Z., et al. (2021) · Food & Function · doi:10.1039/d1fo01352a · Cited by 44
Spike residue 403 affects binding of coronavirus spikes to human ACE2
Zech, F., Schniertshauer, D., Jung, C., Herrmann, A., Cordsmeier, A., Xie, Q., Nchioua, R., Bozzo, C. P., Volčič, M., Koepke, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27180-0 · Cited by 47
Roncato, R., Angelini, J., Pani, A., & Talotta, R. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159140 · Cited by 43
Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccinesPreprint
Bowen, J. E., Sprouse, K. R., Walls, A. C., Mazzitelli, I. G., Logue, J. K., Franko, N., Ahmed, K., Ansari, A. S., Cameroni, E., Gori, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.15.484542 · Cited by 38
Wang, Q., Zhao, Y., Chen, X., & Hong, A. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1817786 · Cited by 40
Kalra, R. S., Tomar, D., Meena, A. S., & Kandimalla, R. J. L. (2020) · Pathogens · doi:10.3390/pathogens9070546 · Cited by 41
Galili, U. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.08.032 · Cited by 40
A comprehensive review on potential therapeutics interventions for COVID-19
Chugh, H., Awasthi, A., Agarwal, Y., Gaur, R. K., Dhawan, G., & Chandra, R. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173741 · Cited by 44
Human early syncytiotrophoblasts are highly susceptible to SARS-CoV-2 infection
Ruan, D., Ye, Z., Yuan, S., Li, Z., Zhang, W., Ong, C. P., Tang, K., Tam, T. T. K. K., Guo, J., Xuan, Y., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100849 · Cited by 42
High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike
Tan, T. J. C., Mou, Z., Lei, R., Ouyang, W. O., Yuan, M., Song, G., Andrabi, R., Wilson, I. A., Kieffer, C., Dai, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37786-1 · Cited by 40
The potential use of bacteria and bacterial derivatives as drug delivery systems for viral infection
Faghihkhorasani, A., Ahmed, H. H., Mashool, N. M., Alwan, M., Assefi, M., Adab, A. H., Yasamineh, S., Gholizadeh, O., & Baghani, M. (2023) · Virology Journal · doi:10.1186/s12985-023-02183-z · Cited by 41
Chen, X., Huang, J., Huang, Y., Chen, J., Huang, Y., Jiang, X., & Shi, Y. (2020) · Human Immunology · doi:10.1016/j.humimm.2020.08.006 · Cited by 39
How SARS-CoV-2 (COVID-19) spreads within infected hosts — what we know so far
Sanyal, S. (2020) · Emerging Topics in Life Sciences · doi:10.1042/etls20200165 · Cited by 44
Chua, K. H., Mohamed, I. N., Yunus, M. H. M., Nor, N. S. M., Kamil, K., Ugusman, A., & Kumar, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.633292 · Cited by 40
Cao, X., Tian, Y., Nguyen, V., Zhang, Y., Gao, C., Yin, R. L., Carver, W. E., Fan, D., Albrecht, H., Cui, T., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202002742rr · Cited by 39
Almasy, K. M., Davies, J. P., & Plate, L. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100120 · Cited by 40
Menezes, M. C. S., Veiga, A. D. M., de Lima, T. M., Ariga, S. K. K., Barbeiro, H. V., Moreira, C. D. L., Pinto, A. A. S., Brandao, R. A., Marchini, J. F. M., de Alencar, J. C. G., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94624-4 · Cited by 42
Advanced Materials for SARS‐CoV‐2 Vaccines
Mabrouk, M. T., Huang, W., Martínez‐Sobrido, L., & Lovell, J. F. (2021) · Advanced Materials · doi:10.1002/adma.202107781 · Cited by 38
Atlas of ACE2 gene expression in mammals reveals novel insights in transmisson of SARS-Cov-2Preprint
Sun, K., Gu, L., Ma, L., & Duan, Y. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.30.015644 · Cited by 38
Winkler, E. S., Bailey, A. L., Kafai, N. M., Nair, S., McCune, B. T., Yu, J., Fox, J. M., Chen, R. E., Earnest, J. T., Keeler, S. P., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.09.196188 · Cited by 40
King, R. G., Silva-Sánchez, A., Peel, J. N., Botta, D., Meza‐Perez, S., Allie, S. R., Schultz, M. D., Liu, M., Bradley, J., Qiu, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.10.331348 · Cited by 40
Amanat, F., Thapa, M., Lei, T., Ahmed, S. M. S., Adelsberg, D. C., Carreño, J. M., Strohmeier, S., Schmitz, A. J., Zafar, S., Zhou, J. Q., et al. (2021) · medRxiv · doi:10.1101/2021.03.07.21253098 · Cited by 41
Silva, A. W. C., da Cunha, A. A., Alves, G. C., Corona, R., Dias, C. A. G. D. M., Nassiri, R., Vedovelli, S., de Araújo, M. H. M., da Souza, K. O., de Oliveira, E., et al. (2020) · Research Society and Development · doi:10.33448/rsd-v9i8.5499 · Cited by 39
Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
Alleva, D. G., Delpero, A. R., Scully, M. M., Murikipudi, S., Ragupathy, R., Greaves, E. K., Sathiyaseelan, T., Haworth, J. R., Shah, N. J., Rao, V., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.09.077 · Cited by 39
Recent Progress on Rapid Lateral Flow Assay-Based Early Diagnosis of COVID-19
Zhang, Y., Chai, Y., Hu, Z., Xu, Z., Li, M., Chen, X., Yang, C., & Liu, J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.866368 · Cited by 40
Prakash, S., Dhanushkodi, N. R., Zayou, L., Ibraim, I. C., Quadiri, A., Coulon, P.-G. A., Tifrea, D. F., Suzer, B., Shaik, A. M., Chilukuri, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328905 · Cited by 42
Ekum, M. I., & Ogunsanya, A. S. (2020) · International Journal of Clinical Biostatistics and Biometrics · doi:10.23937/2469-5831/1510027 · Cited by 43
Differentiation of COVID‐19 from seasonal influenza: A multicenter comparative study
Zhang, J., Ding, D., Huang, X., Zhang, J., Chen, D., Fu, P., Shi, Y., Xu, W., & Tao, Z. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26469 · Cited by 39
Role of Renin-Angiotensin System in Acute Lung Injury Caused by Viral Infection
Gao, Y., Du, Y., Zhang, C., Cheng, C., Yang, H., Jin, Y., Duan, G., & Chen, S. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s265718 · Cited by 41
SARS-CoV-2 transmission via aquatic food animal species or their products: A review
Godoy, M., Kibenge, M., & Kibenge, F. S. B. (2021) · Aquaculture · doi:10.1016/j.aquaculture.2021.736460 · Cited by 39
Vaccine design and delivery approaches for COVID-19
Shahzamani, K., Mahmoudian, F., Ahangarzadeh, S., Ranjbar, M. M., Beikmohammadi, L., Bahrami, S., Mohammadi, E., Esfandyari, S., Alibakhshi, A., & Javanmard, S. H. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108086 · Cited by 41
Insight into COVID-19's epidemiology, pathology, and treatment
Aimrane, A., Laaradia, M. A., Séréno, D., Perrin, P., Draoui, A., Bougadir, B., Hadach, M., Zahir, M., Fdil, N., Hiba, O. E., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e08799 · Cited by 38
Genetic Landscape of the ACE2 Coronavirus Receptor
Yang, Z., Macdonald-Dunlop, E., Chen, J., Zhai, R., Li, T., Richmond, A., Klarić, L., Pirastu, N., Ning, Z., Zheng, C., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.057888 · Cited by 39
Are Older People Really More Susceptible to SARS-CoV-2?
Zhang, S., Yang, Z., Li, Z.-N., Chen, Z.-L., Yue, S.-J., Fu, R.-J., Xu, D.-Q., Zhang, S., & Tang, Y.-P. (2022) · Aging and disease · doi:10.14336/ad.2022.0130 · Cited by 39
Relation between COVID-19 and Guillain-Barré syndrome in adults: a systematic review
Gittermann, L. M. T., Feris, S. V., & Astrid von Oetinger, G. (2020) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.07.005 · Cited by 39
Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies
Abubakar, M. B., Usman, D., Batiha, G. E., Martins, N. A., Malami, I., Ibrahim, K. G., Abubakar, B., Bello, M. B., Muhammad, A. I., Gan, S. H., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.629935 · Cited by 38
Cacciottolo, M., Nice, J. B., Li, Y., LeClaire, M. J., Twaddle, R., Mora, C. L., Adachi, S. Y., Chin, E. R., Young, M., Angeles, J., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00503-23 · Cited by 38
Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects
Huynh, A., Arnold, D. M., Smith, J. W., Moore, J. C., Zhang, A., Chagla, Z., Harvey, B. J., Stacey, H. D., Ang, J. C., Clare, R., et al. (2021) · Viruses · doi:10.3390/v13040697 · Cited by 38
Obakachi, V. A., Kushwaha, N. D., Kushwaha, B., Mahlalela, M. C., Shinde, S., Kehinde, I. A., & Karpoormath, R. V. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130665 · Cited by 38
Ye, F., Lin, X., Chen, Z., Yang, F., Lin, S., Yang, J., Chen, H., Sun, H., Wang, L., Wen, A., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00756-4 · Cited by 37
Chlorhexidine mouthwash reduces the salivary viral load of SARS‐CoV‐2: A randomized clinical trial
Costa, D. D., Brites, C. R., Vaz, S. N., de Santana, D. S., dos Santos, J. N., & Cury, P. R. (2021) · Oral Diseases · doi:10.1111/odi.14086 · Cited by 38
Vitale-Cross, L. A., Szalayova, I., Scoggins, A., Palkovits, M., & Mezey, É. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103981 · Cited by 39
Anderson, E. M., Li, S. H., Awofolaju, M., Eilola, T., Goodwin, E. C., Bolton, M. J., Gouma, S., Manzoni, T. B., Hicks, P. D., Goel, R. R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111496 · Cited by 37
Functional and druggability analysis of the SARS-CoV-2 proteome
Cavasotto, C. N., Sánchez‐Lamas, M., & Maggini, J. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173705 · Cited by 38
The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2
Ho, T., Chen, Y. A., Chan, H.-P., Chang, C.-C., Chuang, K., Lee, C., Yuan, C., Tyan, Y., & Yang, M. (2021) · Vaccines · doi:10.3390/vaccines9101163 · Cited by 40
Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness
Tulimilli, S. V., Dallavalasa, S., Basavaraju, C. G., Rao, V. K., Chikkahonnaiah, P., Madhunapantula, S. V., & Veeranna, R. P. (2022) · Vaccines · doi:10.3390/vaccines10101751 · Cited by 39
2019 Novel coronavirus (COVID-19) overview
Mohammadi, M., Meskini, M., & Pinto, A. L. D. N. (2020) · Journal of Public Health · doi:10.1007/s10389-020-01258-3 · Cited by 37
Archie, S. R., & Cucullo, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113916 · Cited by 37
A lesson from a saboteur: High‐MW kininogen impact in coronavirus‐induced disease 2019
Colarusso, C., Terlizzi, M., Pinto, A., & Sorrentino, R. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15154 · Cited by 38
In silico designing of multi-epitope vaccine construct against human coronavirus infections
Devi, A., & Chaitanya, N. S. N. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1804460 · Cited by 37
McNamara, R. P., Caro‐Vegas, C., Landis, J. T., Moorad, R., Pluta, L., Eason, A. B., Thompson, C. M., Bailey, A., Villamor, F. C. S., Lange, P. T., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108352 · Cited by 39
Havranek, K. E., Jimenez, A. R., Acciani, M. D., Mendoza, M. L., Ballista, J. M. R., Diaz, D., & Brindley, M. A. (2020) · Viruses · doi:10.3390/v12121465 · Cited by 37
Kruglova, N., Siniavin, A., Gushchin, V., & Mazurov, D. (2021) · Viruses · doi:10.3390/v13061133 · Cited by 37
COVID‐19 and the liver – Lessons learned
Herta, T., & Berg, T. (2021) · Liver International · doi:10.1111/liv.14854 · Cited by 38
Malekmohammad, K., & Rafieian‐Kopaei, M. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210705160130 · Cited by 37
Wang, J., Yang, G., Wang, X., Wen, Z., Shuai, L., Luo, J. D., Wang, C., Sun, Z., Liu, R., Ge, J., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00357-z · Cited by 39
SARS-CoV-2 Remains Infectious on Refrigerated Deli Food, Meats, and Fresh Produce for up to 21 Days
Jia, M., Taylor, T. M., Senger, S. M., Ovissipour, R., & Bertke, A. S. (2022) · Foods · doi:10.3390/foods11030286 · Cited by 36
Furuyama, W., Shifflett, K., Pinski, A. N., Griffin, A. J., Feldmann, F., Okumura, A., Gourdine, T., Jankeel, A., Lovaglio, J., Hanley, P. W., et al. (2022) · mBio · doi:10.1128/mbio.03379-21 · Cited by 39
Self-citationMurae, M., Shimizu, Y., Yamamoto, Y., Kobayashi, A., Houri, M., Inoue, T., Irie, T., Gemba, R., Kondo, Y., Nakano, Y., et al. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.01.106 · Cited by 39
Fadlalla, M., Ahmed, M., Ali, M. A. M., Elshiekh, A. A., & Yousef, B. A. (2022) · Current Pharmacology Reports · doi:10.1007/s40495-022-00285-w · Cited by 37
Mazidimoradi, A., Alemzadeh, E., Alemzadeh, E., & Salehiniya, H. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120489 · Cited by 39
Genetic landscape of the ACE2 coronavirus receptor
Yang, Z., Macdonald-Dunlop, E., Chen, J., Prins, B. P., Wheeler, E., Pietzner, M., Peters, J. E., Langenberg, C., Butterworth, A. S., Reiner, A. P., et al. (2022) · Apollo (University of Cambridge) · doi:10.17863/cam.84347 · Cited by 35
A retrospective study of the clinical characteristics of COVID-19 infection in 26 childrenPreprint
Tang, A., Xu, W., Shen, M. Y., Chen, P., Li, G., Liu, Y., & Liu, L. (2020) · medRxiv · doi:10.1101/2020.03.08.20029710 · Cited by 37
Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines
Gaspar, E. B., Prudêncio, C. R., & Gaspari, E. D. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1920272 · Cited by 37
IL-1 Mediates Tissue-Specific Inflammation and Severe Respiratory Failure in COVID-19
Renieris, G., Karakike, E., Gkavogianni, T., Droggiti, D.-E., Stylianakis, E., Andriopoulou, T., Spanou, V. M., Kafousopoulos, D., Netea, M. G., Eugen‐Olsen, J., et al. (2022) · Journal of Innate Immunity · doi:10.1159/000524560 · Cited by 35
ACE2-Independent Bat Sarbecovirus Entry and Replication in Human and Bat Cells
Guo, H., Li, A., Dong, T.-Y., Su, J., Yao, Y., Zhu, Y., Shi, Z., & Letko, M. C. (2022) · mBio · doi:10.1128/mbio.02566-22 · Cited by 36
Self-citationRisk of using hydroxychloroquine as a treatment of COVID-19
Alanagreh, L., Alzoughool, F., & Atoum, M. F. M. (2020) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-200024 · Cited by 36
An overview of key potential therapeutic strategies for combat in the COVID-19 battle
Das, G., Ghosh, S., Garg, S., Ghosh, S., Jana, A., Samat, R., Mukherjee, N., Roy, R., & Ghosh, S. (2020) · RSC Advances · doi:10.1039/d0ra05434h · Cited by 37
ACE2‐based decoy receptors for SARS coronavirus 2
Jing, W., & Procko, E. (2021) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26140 · Cited by 32
Islam, A., Ferdous, J., Islam, S., Sayeed, M. A., Rahman, M. K., Saha, O., Hassan, M. M., & Shirin, T. (2021) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14356 · Cited by 37
Rowland, R. R. R., & Brandariz-Núñez, A. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01199-21 · Cited by 36
Chen, R. E., Gorman, M. J., Zhu, D. Y., Carreño, J. M., Yuan, D., VanBlargan, L. A., Burdess, S., Lauffenburger, D. A., Kim, W., Turner, J. S., et al. (2021) · Med · doi:10.1016/j.medj.2021.11.004 · Cited by 37
Combating SARS-CoV-2: leveraging microbicidal experiences with other emerging/re-emerging viruses
Ijaz, M. K., Sattar, S. A., Rubino, J. R., Nims, R. W., & Gerba, C. P. (2020) · PeerJ · doi:10.7717/peerj.9914 · Cited by 35
Changes of Laboratory Cardiac Markers and Mechanisms of Cardiac Injury in Coronavirus Disease 2019
Li, L., Zhou, Q., & Xu, J. (2020) · BioMed Research International · doi:10.1155/2020/7413673 · Cited by 35
COVID-19 (SARS-CoV-2) pandemic: fears, facts and preventive measures
Ayenigbara, I. O., Adeleke, O. R., Ayenigbara, G. O., Adegboro, J. S., & Olofintuyi, O. O. (2020) · GERMS · doi:10.18683/germs.2020.1208 · Cited by 35
Xi, C., Fazio, A. D., Nadvi, N. A., Patel, K., Xiang, M. S. W., Zhang, H. E., Deshpande, C. N., Low, J. K. K., Wang, X. T., Chen, Y., et al. (2020) · Molecules · doi:10.3390/molecules25225392 · Cited by 36
Metadata
- Authors
- Letko, M., Marzi, A., & Munster, V.
- Affiliations
- National Institutes of Health (US)
- National Institute of Allergy and Infectious Diseases (US)
- Corresponding author
- Letko, Michael
- Munster, Vincent
- Venue
- Nature Microbiology
- Published
- 2020-02-24
- Volume
- 5
- Issue
- 4
- Pages
- 562-569
- ISSN
- 2058-5276 (ISSN-L)
- PMC
- PMC7095430
- OpenAlex
- W3008394341
- Cited by
- 3,109
- References
- 38
- Citations by year
- 2026: 47 · 2025: 122 · 2024: 198 · 2023: 287 · 2022: 571 · 2021: 874 · 2020: 1002
- FWCI
- 89.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature Microbiology (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Funders
- Chinese Center for Disease Control and Prevention
- Chinese Academy of Medical Sciences
- Peking Union Medical College
- National Institute of Allergy and Infectious Diseases
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Zoonotic diseases and public health
- Keywords
- SARS-CoV-2, SARS-CoV, cell entry, ACE2 receptor, zoonotic transmission, viral recombination, cross-species infection
- MeSH terms
- Protein Domains, Betacoronavirus, Receptors, Coronavirus, Angiotensin-Converting Enzyme 2, COVID-19, SARS-CoV-2, Animals, Cell Line, Humans, Peptidyl-Dipeptidase A, Mutation, Pneumonia, Viral, Receptors, Virus, Recombinant Fusion Proteins, Trypsin, Coronavirus Infections, Dipeptidyl Peptidase 4, CD13 Antigens, Severe acute respiratory syndrome-related coronavirus, Virus Internalization, Pandemics, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
